索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]焦佼,侯莉,徐志云,等.终末期肝病模型评分在心血管疾病中的应用[J].国际心血管病杂志,2025,01:32-35.
点击复制

终末期肝病模型评分在心血管疾病中的应用(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2025年01期
页码:
32-35
栏目:
综述
出版日期:
2025-01-25

文章信息/Info

Title:
-
作者:
焦佼; 侯莉; 徐志云; 周炜
200433 海军军医大学第一附属医院（上海长海医院）心血管外科（焦佼，徐志云）；200025 上海交通大学医学院附属第九人民医院整复外科（侯莉）；200120 上海，同济大学附属东方医院重症医学科（周炜）
Author(s):
-
关键词:
终末期肝病模型评分; 心血管疾病; 预后
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2025.01.009
文献标识码:
-
摘要:
终末期肝病模型（MELD）评分作为肝移植手术中的重要评估工具，临床使用简单易行，其是肝移植患者等候移植手术的重要指标，如今越来越多地被用作肝外疾病的评估工具。该文介绍MELD评分在心血管疾病中的应用。
Abstract:
-

参考文献/References

[1] Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31(4):864-871.
[2] Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology,2001, 33(2):464-470.
[3] Singal AK, Kamath PS. Model for end-stage liver disease[J]. J Clin Exp Hepatol, 2013, 3(1):50-60.
[4] Yang JA, Kato TS, Shulman BP, et al. Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support: use of the model of end-stage liver disease (MELD) and MELD eXcluding INR (MELD-XI) scoring system[J]. J Heart Lung Transplant, 2012, 31(6):601-610.
[5] Khurram M, Qayyum W, Umar M, et al. Evaluation of model for end-stage liver disease score cut off values in patients with hepatic encephalopathy[J]. J Ayub Med Coll Abbottabad, 2015, 27(4):886-889.
[6] He HM, He C, You ZB, et al. Association between different versions of the model for end-stage liver disease score and contrast-associated acute kidney injury in patients undergoing elective percutaneous coronary intervention[J]. Circ J, 2022, 86(5):821-830.
[7] Hawkins RB, Young BA, Mehaffey JH, et al. Model for end-stage liver disease score independently predicts mortality in cardiac surgery[J]. Ann Thorac Surg, 2019, 107(6):1713-1719.
[8] Kamath PS, Kim WR. Advanced liver disease study group. The model for end-stage liver disease(MELD)[J]. Hepatology, 2007, 45(3):797-805.
[9] Heuman DM, Mihas AA, Habib A, et al. MELD-XI: a rational approach to "sickest first" liver transplantation in cirrhotic patients requiring anticoagulant therapy[J]. Liver Transpl, 2007, 13(1):30-37.
[10] Gudbjartsson T, Ahlsson A, Geirsson A, et al. Acute type A aortic dissection-a review[J]. Scand Cardiovasc J, 2020, 54(1):1-13.
[11] Wang ZG, Chen T, Ge M, et al. The risk factors and outcomes of preoperative hepatic dysfunction in patients who receive surgical repair for acute type A aortic dissection[J]. J Thorac Dis, 2021, 13(10):5638-5648.
[12] Zhou W, Wang GK, Liu YY, et al. Outcomes and risk factors of postoperative hepatic dysfunction in patients undergoing acute type A aortic dissection surgery[J]. J Thorac Dis, 2019, 11(8):3225-3233.
[13] Lin XF, Xie LF, Jiang DB, et al. Hepatic dysfunction and adverse outcomes after total arch repair of acute type a aortic dissection:application of the MELD-XI score[J]. BMC Cardiovasc Disord, 2022, 22(1):491.
[14] 刘楠, 孙立忠, 常谦, 等. 主动脉夹层手术后肝功能不全死亡的相关危险因素分析[J]. 中华胸心血管外科杂志, 2011, 27(3):165-167.
[15] Achouh PE, Madsen K, Miller CC 3rd, et al. Gastrointestinal complications after descending thoracic and thoracoabdominal aortic repairs: a 14-year experience[J]. J Vasc Surg, 2006, 44(3):442-446.
[16] Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients[J]. J Heart Lung Transplant,2023, 42(5):e1-e141.
[17] Chokshi A, Cheema FH, Schaefle KJ, et al. Hepatic dysfunction and survival after orthotopic heart transplantation: application of the MELD scoring system for outcome prediction[J]. J Heart Lung Transplant, 2012, 31(6):591-600.
[18] Deo SV, Al-Kindi SG, Altarabsheh SE, et al. Model for end-stage liver disease excluding international normalized ratio (MELD-XI) score predicts heart transplant outcomes: evidence from the registry of the United Network for Organ Sharing[J]. J Heart Lung Transplant, 2016, 35(2):222-227.
[19] Farr M, Mitchell J, Lippel M, et al. Combination of liver biopsy with MELD-XI scores for post-transplant outcome prediction in patients with advanced heart failure and suspected liver dysfunction[J]. J Heart Lung Transplant, 2015, 34(7):873-882.
[20] Grimm JC, Magruder JT, Do N, et al. Modified model for end-stage liver disease eXcluding INR (MELD-XI) score predicts early death after pediatric heart transplantation[J]. Ann Thorac Surg, 2016, 101(2):730-735.
[21] Grimm JC, Shah AS, Magruder JT, et al. MELD-XI score predicts early mortality in patients after heart transplantation[J]. Ann Thorac Surg, 2015, 100(5):1737-1743.
[22] Vanhuyse F, Maureira P, Mattei MF, et al. Use of the model for end-stage liver disease score for guiding clinical decision-making in the selection of patients for emergency cardiac transplantation[J]. Eur J Cardiothorac Surg, 2013, 44(1):134-138.
[23] Amdani S, Simpson KE, Thrush P, et al. Hepatorenal dysfunction assessment with the model for end-stage liver disease excluding INR score predicts worse survival after heart transplant in pediatric Fontan patients[J]. J Thorac Cardiovasc Surg, 2022, 163(4):1462-1473.e12.
[24] Moraes A, Fonseca-Neto O. The use of MELD scroe (model for end-stage liver disease) and derivatives in cardiac transplantation[J]. Arq Bras Cir Dig, 2018, 31(2):e1370.
[25] F?rber G, Marx J, Scherag A, et al. Risk stratification for isolated tricuspid valve surgery assisted using the model for end-stage liver disease score[J]. J Thorac Cardiovasc Surg, 2023, 166(5):1433-1441.e1.
[26] DeRoo SC, Aldea GS. Commentary: mind MELD complete: can the model for end-stage liver disease (MELD) score predict risk in isolated tricuspid surgery?[J]. J Thorac Cardiovasc Surg, 2023, 166(5):1442-1443.
[27] Xu HJ, Wang H, Chen SS, et al. Prognostic value of modified model for end-stage liver disease score in patients undergoing isolated tricuspid valve replacement[J]. Front Cardiovasc Med, 2022, 9:932142.
[28] Kiris T, Avci E, ?elik A. Combined value of left ventricular ejection fraction and the model for end-stage liver disease (MELD) score for predicting mortality in patients with acute coronary syndrome who were undergoing percutaneous coronary intervention[J]. BMC Cardiovasc Disord, 2018, 18(1):44.
[29] Dolapoglu A, Avci E, Argan O, et al. Impact of model for end-stage liver disease (MELD) score for mortality in patients undergoing coronary bypass surgery[J]. Bratisl Lek Listy, 2021, 122(2):125-131.
[30] Pidborochynski T, Bozso SJ, Buchholz H, et al. Predicting outcomes following short-term ventricular assist device implant with the MELD-XI score[J]. Artif Organs, 2023, 47(11):1752-1761.
[31] Kim MS, Kato TS, Farr M, et al. Hepatic dysfunction in ambulatory patients with heart failure: application of the MELD scoring system for outcome prediction[J]. J Am Coll Cardiol, 2013, 61(22):2253-2261.
[32] Lin ZB, Liu X, Xiao L, et al. The MELD-XI score predicts 3-year mortality in patients with chronic heart failure[J]. Front Cardiovasc Med, 2022, 9:985503.
[33] Biegus J, Zymliński R, Sokolski M, et al. Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure[J]. Eur J Heart Fail, 2016, 18(12):1518-1521.
[34] Grodin JL, Gallup D, Anstrom KJ, et al. Implications of alternative hepatorenal prognostic scoring systems in acute heart failure (from DOSE-AHF and ROSE-AHF)[J]. Am J Cardiol, 2017, 119(12):2003-2009.

备注/Memo

备注/Memo:
基金项目：上海市卫生健康系统重点扶持学科（2023ZDFC0104）
通信作者：周炜， E-mail：zhouwei090404@163.com
更新日期/Last Update: 2025-02-10